The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after ...
As radiotherapy becomes more strategically integrated around CAR T-cell therapy in multiple myeloma, clinicians face a choice ...
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose ...
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus ...
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration ...
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive ...
Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye ...
The FDA has accepted a resubmitted biologics license application (BLA) for tabelecleucel (tab-cel; Ebvallo), with a proposed ...
Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results